Publications by authors named "E Gerstner"
Article Synopsis
- Recent advancements in deep learning (DL) are enhancing clinical tools for analyzing brain tumors in MRI, aiding in tumor segmentation, quantification, and classification.
- DL provides objective and consistent measurements essential for accurate diagnosis, treatment planning, and tracking disease progression.
- Additionally, DL can help personalize medicine by predicting tumor characteristics and patient prognoses, with the review assessing both current uses and future possibilities.
Context: Chimeric antigen receptor (CAR) T cell therapy is an exciting modality of immunotherapy that has revolutionized the treatment of hematologic malignancies. However, translating this success to malignant gliomas such as glioblastoma (GBM) and diffuse midline glioma (DMG) remains a formidable challenge due to multiple biologic, anatomic, and immunologic factors. Despite these hurdles, a number of clinical trials deployed over the last decade have increased optimism for the potential of CAR T cell therapy in glioma treatment.
View Article and Find Full Text PDFArticle Synopsis
- Radiation therapy (RT) for glioma can lead to neurotoxicity, and this study compares the effects of proton RT (PRT) versus photon RT (XRT) on brain imaging metrics in patients.
- In a study of 34 patients with WHO grade 2-3 gliomas, significant ventricular volume increases were noted in both RT groups, with XRT showing greater brain volume loss (26.55%) compared to PRT (12.03%) after two years.
- While PRT patients did not show overall cognitive decline, individual cognitive performance correlated with brain volume loss, indicating the need for further research on long-term cognitive effects following radiation treatment.
Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?
Curr Treat Options Oncol
May 2024
Immunotherapy for glioblastoma (GBM) remains an intensive area of investigation. Given the seismic impact of cancer immunotherapy across a range of malignancies, there is optimism that harnessing the power of immunity will influence GBM as well. However, despite several phase 3 studies, there are still no FDA-approved immunotherapies for GBM.
View Article and Find Full Text PDF